<DOC>
	<DOCNO>NCT00040807</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness irinotecan docetaxel treat patient metastatic locally recurrent head neck cancer .</brief_summary>
	<brief_title>Irinotecan Docetaxel Treating Patients With Metastatic Locally Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient metastatic locally recurrent head neck cancer treat irinotecan docetaxel . - Determine progression-free overall survival patient treat regimen . - Determine toxic effect regimen patient . - Correlate angiogenesis marker cyclooxygenase-2 expression response survival patient treat regimen . - Correlate UGT1A1 genotype toxic effect regimen patient . OUTLINE : This multicenter study . Patients stratify accord prior chemotherapy ( prior chemotherapy locally recurrent metastatic disease 6 month since prior chemotherapy primary therapy v 1 prior chemotherapy regimen locally recurrent metastatic disease le 6 month since prior chemotherapy primary therapy ) . Patients receive docetaxel IV 60 minute follow irinotecan IV 30 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 32-72 patient ( 16-36 per stratum ) accrue study within 6-14 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma head neck Squamous cell carcinoma No WHO grade II III nasopharyngeal carcinoma ( welldifferentiated nasopharyngeal carcinoma allow ) Metastatic locally recurrent disease consider incurable locoregional therapy Unidimensionally measurable disease outside previously irradiate field unless document progressive disease histologically confirm residual carcinoma least 8 week completion radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST ALT less 2.5 time upper limit normal ( ULN ) alkaline phosphatase normal OR Alkaline phosphatase less 4 time ULN AST ALT normal Renal : Creatinine le 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No active infection No preexisting grade 2 great peripheral neuropathy No concurrent medical condition would preclude study participation No hypersensitivity drug formulate Polysorbate 80 No malignancy within past 3 year except curatively treat squamous cell basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior biologic therapy Any number prior biologic therapy ( e.g. , chimeric antibody kinase inhibitor ) allow No concurrent filgrastim ( GCSF ) Chemotherapy : At least 4 week since prior chemotherapy No prior docetaxel irinotecan No 1 prior chemotherapy regimen recurrent metastatic disease Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recurrent metastatic disease recover Surgery : Recovered prior surgery Other : No concurrent antiepileptics No concurrent cyclosporine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>